AnnaCarin Horne
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
AnnaCarin Horne has a total of 507 co-authors. Here are the top co-authors by number of shared publications:
- Jan-Inge Henter
Childhood Cancer Research Unit, Department of Women’s and Children’s Health, Karolinska Institute, Stockholm, Sweden
21 shared publications Gritta Janka
Department of Pediatric Hematology and Oncology, University Medical Center Hamburg, Hamburg, Germany
14 shared publications- Maurizio Aricò
Interdisciplinary Department of Medicine, Aldo Moro University of Bari, Bari, Italy
12 shared publications Kai Lehmberg
Division of Pediatric Stem Cell Transplantation and Immunology, Department of Pediatric Hematology and Oncology, University Medical Center Hamburg, Hamburg, Germany
10 shared publications- Francesca Bovis
Department of Health Sciences (DISSAL), University of Genova, Genova, Italy
8 shared publications Stephan Ladisch
Center for Cancer and Immunology Research, Children’s Research Institute, Children’s National Medical Center, Washington, DC
8 shared publications
Latest Publications
- Open Access
- 10 November 2026
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 3 (1)
Truncating variants reveal functional divergence of the SAMD9 and SAMD9L paralogues
Germline gain-of-function (GoF) variants in the paralogous sterile alpha motif domain containing 9 (SAMD9) and SAMD9-like (SAMD9L) genes cause myelodysplasia, primary immunodeficiencies, and neurological disorders. Predicting the functional consequences of individual variants, however, remains challenging, owing partly to the complexity of these large, multidomain proteins. Here, we functionally characterized several rare patient-derived SAMD9/9L variants, identifying multiple novel GoF and loss-of-function (LoF) variants, including SAMD9L p.C883X—the shortest documented SAMD9L GoF truncation within the NTPase domain. SAMD9L NTPase domain truncations are associated with severe, early-onset pathology, yet despite the high structural and sequence similarity between the two proteins, analogous truncating variants have not been reported in SAMD9 patients. To examine whether this reflects a fundamental difference, we generated multiple homologous SAMD9 truncations, which, unlike their SAMD9L counterparts, exhibited LoF rather than GoF activity. Additionally, established computational pathogenicity predictors failed to identify pathogenic variants or distinguish GoF from LoF. Collectively, these results demonstrate that functional outcomes in SAMD9/9L cannot be reliably inferred from sequence, structure, or computational prediction alone, underscoring the importance of empirical characterization.
- 10 November 2026
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 3 (1)
Open AccessTruncating variants reveal functional divergence of the SAMD9 and SAMD9L paralogues
Germline gain-of-function (GoF) variants in the paralogous sterile alpha motif domain containing 9 (SAMD9) and SAMD9-like (SAMD9L) genes cause myelodysplasia, primary immunodeficiencies, and neurological disorders. Predicting the functional consequences of individual variants, however, remains challenging, owing partly to the complexity of these large, multidomain proteins. Here, we functionally characterized several rare patient-derived SAMD9/9L variants, identifying multiple novel GoF and loss-of-function (LoF) variants, including SAMD9L p.C883X—the shortest documented SAMD9L GoF truncation within the NTPase domain. SAMD9L NTPase domain truncations are associated with severe, early-onset pathology, yet despite the high structural and sequence similarity between the two proteins, analogous truncating variants have not been reported in SAMD9 patients. To examine whether this reflects a fundamental difference, we generated multiple homologous SAMD9 truncations, which, unlike their SAMD9L counterparts, exhibited LoF rather than GoF activity. Additionally, established computational pathogenicity predictors failed to identify pathogenic variants or distinguish GoF from LoF. Collectively, these results demonstrate that functional outcomes in SAMD9/9L cannot be reliably inferred from sequence, structure, or computational prediction alone, underscoring the importance of empirical characterization.
- 2 November 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (21) , 7429-7449
Central nervous system involvement in children with hemophagocytic lymphohistiocytosis: an HLH-2004 study report
Hemophagocytic lymphohistiocytosis (HLH) is a hyperinflammatory syndrome with an inherited form (primary HLH [pHLH]), of which familial HLH (FHL) is most prevalent, and an acquired (non-Mendelian) form (secondary HLH); both potentially fatal. As more patients survive, evaluating long-term morbidity, especially neurological complications, is important. Here, we report on central nervous system involvement at onset, its impact on mortality and morbidity, and long-term follow-up in 365 children aged <18 years enrolled in the prospective multinational HLH-2004 study. This treatment included etoposide; dexamethasone; cyclosporine; and, for selected patients, intrathecal methotrexate/prednisolone; followed by hematopoietic stem cell transplantation (HSCT) for pHLH. At diagnosis, 33% had neurological symptoms and 57% abnormal cerebral spinal fluid (CSF); 33% and 73%, respectively, in children with verified FHL. Elevated CSF protein was associated with inferior survival in univariate analyses, and multivariate analyses revealed reduced survival in children with both neurological symptoms and abnormal CSF. Overall, 32% of post-HSCT long-term survivors had neurological symptoms at last follow-up, more often in children with abnormal CSF at diagnosis; psychomotor retardation affected 25%, seizures 11%, and attention deficit hyperactivity disorder (ADHD)/autism 10% (at least). Seizures and psychomotor retardation were detected before HSCT in approximately half of children who received HSCT; however, at least 3 years after HSCT in one-third. The median time for reporting ADHD/autism was 5 years after HSCT. Late neurological complications were reported in 7% of long-term survivors without HSCT. In conclusion, late neurological complications remain a major concern in pHLH, CSF evaluation at diagnosis is valuable, and long follow-up is important because complications may be diagnosed late. This trial was registered at www.clinicaltrials.gov as #NCT00426101.
- 2 November 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (21) , 7429-7449
Central nervous system involvement in children with hemophagocytic lymphohistiocytosis: an HLH-2004 study report
Hemophagocytic lymphohistiocytosis (HLH) is a hyperinflammatory syndrome with an inherited form (primary HLH [pHLH]), of which familial HLH (FHL) is most prevalent, and an acquired (non-Mendelian) form (secondary HLH); both potentially fatal. As more patients survive, evaluating long-term morbidity, especially neurological complications, is important. Here, we report on central nervous system involvement at onset, its impact on mortality and morbidity, and long-term follow-up in 365 children aged <18 years enrolled in the prospective multinational HLH-2004 study. This treatment included etoposide; dexamethasone; cyclosporine; and, for selected patients, intrathecal methotrexate/prednisolone; followed by hematopoietic stem cell transplantation (HSCT) for pHLH. At diagnosis, 33% had neurological symptoms and 57% abnormal cerebral spinal fluid (CSF); 33% and 73%, respectively, in children with verified FHL. Elevated CSF protein was associated with inferior survival in univariate analyses, and multivariate analyses revealed reduced survival in children with both neurological symptoms and abnormal CSF. Overall, 32% of post-HSCT long-term survivors had neurological symptoms at last follow-up, more often in children with abnormal CSF at diagnosis; psychomotor retardation affected 25%, seizures 11%, and attention deficit hyperactivity disorder (ADHD)/autism 10% (at least). Seizures and psychomotor retardation were detected before HSCT in approximately half of children who received HSCT; however, at least 3 years after HSCT in one-third. The median time for reporting ADHD/autism was 5 years after HSCT. Late neurological complications were reported in 7% of long-term survivors without HSCT. In conclusion, late neurological complications remain a major concern in pHLH, CSF evaluation at diagnosis is valuable, and long follow-up is important because complications may be diagnosed late. This trial was registered at www.clinicaltrials.gov as #NCT00426101.
- Open Access
- 22 May 2026
- Published by Taylor & Francis in Scandinavian Journal of Rheumatology
- Vol. 55 (5) , 1-7
Avacopan in a compassionate use programme for severe anti-neutrophil cytoplasmic antibody-associated vasculitis in Sweden
Avacopan (AVAC), an oral selective C5a receptor inhibitor, has been approved for treatment in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Outside randomized controlled studies, real-world data are scarce. The aim of this study was to provide further insight into the clinical experience of AVAC. We analysed data from 16 patients with severe AAV included in an AVAC compassionate use programme. Disease activity was estimated with the Birmingham Vasculitis Activity Score (BVAS). Fatigue was assessed using the Multidimensional Assessment of Fatigue (MAF). Thirteen patients (81%) were diagnosed with granulomatosis with polyangiitis (GPA) and three (19%) with microscopic polyangiitis. The mean age at AVAC initiation was 51 (range 16-74) years. The median [interquartile range (IQR)] BVAS score was 10 (3.25-13.25) at baseline and 0 (0-0) at 6 months (p < 0.0001). All but one reached clinical remission. Prednisolone was tapered from a median (IQR) dose of 25 (20-60) to 2.5 (0-5) mg/day at 6 months (p = 0.0001). Eight patients discontinued prednisolone [median time 2.5 month1 week to 10 months)]. The median (IQR) estimated glomerular filtration rate in patients with renal AAV (n = 10) increased from 50 (13-75) to 58 (15.5-88) mL/min/1.73 m2 at 6 months (p = 0.055). One patient progressed to end-stage kidney disease, while another was able to discontinue haemodialysis. Serious adverse events were seen in five of the 16 patients (31.3%). The MAF score decreased, with a mean difference of 6.65 (p = 0.05) at 6 months. The use of AVAC in a case series with mainly GPA patients led to rapid clinical improvement, reduction of corticosteroid doses, and improvement in fatigue. The findings demonstrate beneficial effects of AVAC as add-on therapy in severe AAV.
- 22 May 2026
- Published by Taylor & Francis in Scandinavian Journal of Rheumatology
- Vol. 55 (5) , 1-7
Open AccessAvacopan in a compassionate use programme for severe anti-neutrophil cytoplasmic antibody-associated vasculitis in Sweden
Avacopan (AVAC), an oral selective C5a receptor inhibitor, has been approved for treatment in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Outside randomized controlled studies, real-world data are scarce. The aim of this study was to provide further insight into the clinical experience of AVAC. We analysed data from 16 patients with severe AAV included in an AVAC compassionate use programme. Disease activity was estimated with the Birmingham Vasculitis Activity Score (BVAS). Fatigue was assessed using the Multidimensional Assessment of Fatigue (MAF). Thirteen patients (81%) were diagnosed with granulomatosis with polyangiitis (GPA) and three (19%) with microscopic polyangiitis. The mean age at AVAC initiation was 51 (range 16-74) years. The median [interquartile range (IQR)] BVAS score was 10 (3.25-13.25) at baseline and 0 (0-0) at 6 months (p < 0.0001). All but one reached clinical remission. Prednisolone was tapered from a median (IQR) dose of 25 (20-60) to 2.5 (0-5) mg/day at 6 months (p = 0.0001). Eight patients discontinued prednisolone [median time 2.5 month1 week to 10 months)]. The median (IQR) estimated glomerular filtration rate in patients with renal AAV (n = 10) increased from 50 (13-75) to 58 (15.5-88) mL/min/1.73 m2 at 6 months (p = 0.055). One patient progressed to end-stage kidney disease, while another was able to discontinue haemodialysis. Serious adverse events were seen in five of the 16 patients (31.3%). The MAF score decreased, with a mean difference of 6.65 (p = 0.05) at 6 months. The use of AVAC in a case series with mainly GPA patients led to rapid clinical improvement, reduction of corticosteroid doses, and improvement in fatigue. The findings demonstrate beneficial effects of AVAC as add-on therapy in severe AAV.
- Open Access
- 20 November 2025
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 85 (4) , 715-729
A de novo dominant-negative PSMB8 mutation causes severe CANDLE/PRAAS due to arrested proteasome biogenesis
- 20 November 2025
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 85 (4) , 715-729
Open AccessA de novo dominant-negative PSMB8 mutation causes severe CANDLE/PRAAS due to arrested proteasome biogenesis
- Open Access
- 26 September 2025
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 157 (2) , 486-494
Late effects after hematopoietic stem cell transplantation in patients with HLH: A Histiocyte Society, PDWP, IEWP, and TCWP EBMT Study
- 26 September 2025
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 157 (2) , 486-494
Open AccessLate effects after hematopoietic stem cell transplantation in patients with HLH: A Histiocyte Society, PDWP, IEWP, and TCWP EBMT Study
- Open Access
- 1 August 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (3)
Biological therapies in paediatric Behçet’s disease: results of an international collaborative study by the PRES Vasculitis Working Party
Objective: This study aims to examine the indications for paediatric rheumatologists to use biologic therapies in childhood Behçet’s disease (BD), as well as the efficacy, safety and remission rates of such treatments. We also compare demographic and clinical characteristics of Turkish and European cohorts. Methods: In this multicentric retrospective study, the data of 109 paediatric BD (pedBD) patients diagnosed before 18 years of age, obtained from Pediatric Rheumatology European Society (PRES) vasculitis study group, which involves 19 centres across six countries were analysed. Results: Of the patients, 64 were from Turkey and 45 from Europe. The primary indications for initiating biologics were ocular (40.4%), mucocutaneous (22.9%) and neurologic (17.4%) involvement. TNF-α inhibitors were used in 90.8% of cases, with adalimumab (ADA, 59 patients) and infliximab (IFX, 38 patients) being the most commonly prescribed agents. Skin involvement was more common in Turkish cohort compared with European cohort (P < 0.01), while other organ/system involvement was similar. The interval between symptom onset and diagnosis was longer in the European group. Though not significant, biological therapies were initiated earlier and had longer duration in the European cohort. Remission rates were similar in patients receiving ADA and IFX; however, patients receiving ADA experienced a faster decline in disease activity scores, but the difference was not significant (P = 0.2). Only one serious infection was reported, and no malignancy/autoimmune disease were observed. Conclusion: Biologic therapies exhibit robust efficacy and an acceptable safety profile in pedBD. The study emphasizes ocular, mucocutaneous and neurological involvement as principal indications for initiating biologics and offers regional insights into therapeutic strategies.
- 1 August 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (3)
Open AccessBiological therapies in paediatric Behçet’s disease: results of an international collaborative study by the PRES Vasculitis Working Party
Objective: This study aims to examine the indications for paediatric rheumatologists to use biologic therapies in childhood Behçet’s disease (BD), as well as the efficacy, safety and remission rates of such treatments. We also compare demographic and clinical characteristics of Turkish and European cohorts. Methods: In this multicentric retrospective study, the data of 109 paediatric BD (pedBD) patients diagnosed before 18 years of age, obtained from Pediatric Rheumatology European Society (PRES) vasculitis study group, which involves 19 centres across six countries were analysed. Results: Of the patients, 64 were from Turkey and 45 from Europe. The primary indications for initiating biologics were ocular (40.4%), mucocutaneous (22.9%) and neurologic (17.4%) involvement. TNF-α inhibitors were used in 90.8% of cases, with adalimumab (ADA, 59 patients) and infliximab (IFX, 38 patients) being the most commonly prescribed agents. Skin involvement was more common in Turkish cohort compared with European cohort (P < 0.01), while other organ/system involvement was similar. The interval between symptom onset and diagnosis was longer in the European group. Though not significant, biological therapies were initiated earlier and had longer duration in the European cohort. Remission rates were similar in patients receiving ADA and IFX; however, patients receiving ADA experienced a faster decline in disease activity scores, but the difference was not significant (P = 0.2). Only one serious infection was reported, and no malignancy/autoimmune disease were observed. Conclusion: Biologic therapies exhibit robust efficacy and an acceptable safety profile in pedBD. The study emphasizes ocular, mucocutaneous and neurological involvement as principal indications for initiating biologics and offers regional insights into therapeutic strategies.
- Open Access
- 22 August 2024
- Published by American Society of Hematology in Blood
- Vol. 144 (8) , 873-887
Efficacy of T-cell assays for the diagnosis of primary defects in cytotoxic lymphocyte exocytosis
Primary hemophagocytic lymphohistiocytosis (HLH) is a life-threatening disorder associated with autosomal recessive variants in genes required for perforin-mediated lymphocyte cytotoxicity. A rapid diagnosis is crucial for successful treatment. Although defective cytotoxic T lymphocyte (CTL) function causes pathogenesis, quantification of natural killer (NK)–cell exocytosis triggered by K562 target cells currently represents a standard diagnostic procedure for primary HLH. We have prospectively evaluated different lymphocyte exocytosis assays in 213 patients referred for evaluation for suspected HLH and related hyperinflammatory syndromes. A total of 138 patients received a molecular diagnosis consistent with primary HLH. Assessment of Fc receptor–triggered NK-cell and T-cell receptor (TCR)–triggered CTL exocytosis displayed higher sensitivity and improved specificity for the diagnosis of primary HLH than routine K562 cell–based assays, with these assays combined providing a sensitivity of 100% and specificity of 98.3%. By comparison, NK-cell exocytosis after K562 target cell stimulation displayed a higher interindividual variability, in part explained by differences in NK-cell differentiation or large functional reductions after shipment. We thus recommend combined analysis of TCR-triggered CTL and Fc receptor–triggered NK-cell exocytosis for the diagnosis of patients with suspected familial HLH or atypical manifestations of congenital defects in lymphocyte exocytosis.
- 22 August 2024
- Published by American Society of Hematology in Blood
- Vol. 144 (8) , 873-887
Open AccessEfficacy of T-cell assays for the diagnosis of primary defects in cytotoxic lymphocyte exocytosis
Primary hemophagocytic lymphohistiocytosis (HLH) is a life-threatening disorder associated with autosomal recessive variants in genes required for perforin-mediated lymphocyte cytotoxicity. A rapid diagnosis is crucial for successful treatment. Although defective cytotoxic T lymphocyte (CTL) function causes pathogenesis, quantification of natural killer (NK)–cell exocytosis triggered by K562 target cells currently represents a standard diagnostic procedure for primary HLH. We have prospectively evaluated different lymphocyte exocytosis assays in 213 patients referred for evaluation for suspected HLH and related hyperinflammatory syndromes. A total of 138 patients received a molecular diagnosis consistent with primary HLH. Assessment of Fc receptor–triggered NK-cell and T-cell receptor (TCR)–triggered CTL exocytosis displayed higher sensitivity and improved specificity for the diagnosis of primary HLH than routine K562 cell–based assays, with these assays combined providing a sensitivity of 100% and specificity of 98.3%. By comparison, NK-cell exocytosis after K562 target cell stimulation displayed a higher interindividual variability, in part explained by differences in NK-cell differentiation or large functional reductions after shipment. We thus recommend combined analysis of TCR-triggered CTL and Fc receptor–triggered NK-cell exocytosis for the diagnosis of patients with suspected familial HLH or atypical manifestations of congenital defects in lymphocyte exocytosis.
- Open Access
- 12 May 2023
- Published by Wiley in ACR Open Rheumatology
- Vol. 5 (5) , 277-284
Risk of Psychiatric Disorders in Juvenile Idiopathic Arthritis: Population‐ and Sibling‐Controlled Cohort and Cross‐Sectional Analyses
Objective: The objective of this study was to examine the incidence and accumulated burden of psychiatric disorders in juvenile idiopathic arthritis (JIA) relative to the general population (GP) and to their same‐sex siblings.Methods: We performed an observational register‐based study from July 1, 2006, to December 31, 2020, with three different study population contrasts: 1) patients with incident JIA versus five age‐ and sex‐matched GP individuals (cohort), 2) patients with incident JIA versus full same‐sex siblings (cohort), and 3) patients with prevalent JIA at age 18 versus matched GP individuals (cross‐sectional). We investigated six groups of psychiatric disorders defined via International Classification of Diseases, Tenth Revision codes: mood and anxiety, suicidal behavior, eating, sleeping, substance use, psychotic, plus an overall combined outcome (ie, at least one of the six). Incidences rates were compared through Cox regression (contrasts 1 and 2) and logistic regression (contrast 3), all adjusted for demographics, comorbidities, and proxies for socioeconomic status.Results: During 25,141 person‐years of follow‐up of 4939 incident patients with JIA, the incidence of the overall combined outcome was 20.1 per 1000 person‐years in patients with JIA versus 13.1 per 1000 person‐years in the GP (adjusted hazard ratio [HR] = 1.49 [95% confidence interval: 1.35‐1.65]). The three most elevated HRs were obtained for sleeping disorder (1.91 [1.41‐2.59]), suicidal behavior (1.60 [1.23‐2.07]), and mood and anxiety disorders (1.46 [1.30‐1.64]). The comparison of patients with JIA (n = 1815) with their siblings (n = 2050) for the overall combined outcome resulted in a nonstatistically significant HR (1.16 [0.82‐1.64]). By age 18, patients with JIA were more likely to have been diagnosed with any psychiatric disorder (adjusted odds ratio = 1.37 [1.25‐1.50]).Conclusion: There is an increased burden of psychiatric morbidity in JIA, which holds both individual and familial components.
- 12 May 2023
- Published by Wiley in ACR Open Rheumatology
- Vol. 5 (5) , 277-284
Open AccessRisk of Psychiatric Disorders in Juvenile Idiopathic Arthritis: Population‐ and Sibling‐Controlled Cohort and Cross‐Sectional Analyses
Objective: The objective of this study was to examine the incidence and accumulated burden of psychiatric disorders in juvenile idiopathic arthritis (JIA) relative to the general population (GP) and to their same‐sex siblings.Methods: We performed an observational register‐based study from July 1, 2006, to December 31, 2020, with three different study population contrasts: 1) patients with incident JIA versus five age‐ and sex‐matched GP individuals (cohort), 2) patients with incident JIA versus full same‐sex siblings (cohort), and 3) patients with prevalent JIA at age 18 versus matched GP individuals (cross‐sectional). We investigated six groups of psychiatric disorders defined via International Classification of Diseases, Tenth Revision codes: mood and anxiety, suicidal behavior, eating, sleeping, substance use, psychotic, plus an overall combined outcome (ie, at least one of the six). Incidences rates were compared through Cox regression (contrasts 1 and 2) and logistic regression (contrast 3), all adjusted for demographics, comorbidities, and proxies for socioeconomic status.Results: During 25,141 person‐years of follow‐up of 4939 incident patients with JIA, the incidence of the overall combined outcome was 20.1 per 1000 person‐years in patients with JIA versus 13.1 per 1000 person‐years in the GP (adjusted hazard ratio [HR] = 1.49 [95% confidence interval: 1.35‐1.65]). The three most elevated HRs were obtained for sleeping disorder (1.91 [1.41‐2.59]), suicidal behavior (1.60 [1.23‐2.07]), and mood and anxiety disorders (1.46 [1.30‐1.64]). The comparison of patients with JIA (n = 1815) with their siblings (n = 2050) for the overall combined outcome resulted in a nonstatistically significant HR (1.16 [0.82‐1.64]). By age 18, patients with JIA were more likely to have been diagnosed with any psychiatric disorder (adjusted odds ratio = 1.37 [1.25‐1.50]).Conclusion: There is an increased burden of psychiatric morbidity in JIA, which holds both individual and familial components.
- 15 February 2021
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 48 (10) , 1596-1602
Efficacy of Moderately Dosed Etoposide in Macrophage Activation Syndrome–Hemophagocytic Lymphohistiocytosis
Objective: Macrophage activation syndrome (MAS) constitutes 1 subtype of the hyperinflammatory syndrome hemophagocytic lymphohistiocytosis (HLH), and the term MAS-HLH was recently proposed for HLH with underlying autoimmune/autoinflammatory conditions. The mortality of MAS-HLH has been estimated at 5–10%. Here we report our experiences with moderately dosed etoposide in severe MAS-HLH; the objective was to effectively reduce severe hyperinflammatory activity with limited side effects.Methods: In addition to conventional antiinflammatory treatment, moderately dosed etoposide was administered to 7 children affected by rapidly progressing MAS-HLH with central nervous system (n = 5) and/or pulmonary (n = 5) involvement. Three had underlying systemic juvenile idiopathic arthritis (sJIA), 2 had atypical sJIA (no arthritis at diagnosis), and 2 had systemic lupus erythematosus. We performed lymphocyte cytotoxicity analyses in all 7 and genetic analyses in 6.Results: All children promptly responded to moderately dosed etoposide (50–100 mg/m2 once weekly), added to conventional MAS-HLH treatment that was considered insufficient. The mean accumulated etoposide dose was 671 mg/m2 (range 300–1050 mg/m2) as compared to 1500 mg/m2 recommended in the first 8 weeks of the HLH-94/HLH-2004 protocols. One child developed neutropenic fever and another neutropenic sepsis (neutrophils 0.3 × 109/L at therapy onset). Five of 7 children had low percentages (< 5%) of circulating natural killer (NK) cells prior to or in association with diagnosis; NK cell activity was pathologically low in 2 of 5 children studied. Disease-causing variants in HLH-associated genes were not found. All children were alive at latest follow-up (2–9 yrs after onset); neurological symptoms had normalized in 4 of 5 affected children.Conclusion: Moderately dosed etoposide may be beneficial in severe and/or refractory MAS-HLH.
- 15 February 2021
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 48 (10) , 1596-1602
Efficacy of Moderately Dosed Etoposide in Macrophage Activation Syndrome–Hemophagocytic Lymphohistiocytosis
Objective: Macrophage activation syndrome (MAS) constitutes 1 subtype of the hyperinflammatory syndrome hemophagocytic lymphohistiocytosis (HLH), and the term MAS-HLH was recently proposed for HLH with underlying autoimmune/autoinflammatory conditions. The mortality of MAS-HLH has been estimated at 5–10%. Here we report our experiences with moderately dosed etoposide in severe MAS-HLH; the objective was to effectively reduce severe hyperinflammatory activity with limited side effects.Methods: In addition to conventional antiinflammatory treatment, moderately dosed etoposide was administered to 7 children affected by rapidly progressing MAS-HLH with central nervous system (n = 5) and/or pulmonary (n = 5) involvement. Three had underlying systemic juvenile idiopathic arthritis (sJIA), 2 had atypical sJIA (no arthritis at diagnosis), and 2 had systemic lupus erythematosus. We performed lymphocyte cytotoxicity analyses in all 7 and genetic analyses in 6.Results: All children promptly responded to moderately dosed etoposide (50–100 mg/m2 once weekly), added to conventional MAS-HLH treatment that was considered insufficient. The mean accumulated etoposide dose was 671 mg/m2 (range 300–1050 mg/m2) as compared to 1500 mg/m2 recommended in the first 8 weeks of the HLH-94/HLH-2004 protocols. One child developed neutropenic fever and another neutropenic sepsis (neutrophils 0.3 × 109/L at therapy onset). Five of 7 children had low percentages (< 5%) of circulating natural killer (NK) cells prior to or in association with diagnosis; NK cell activity was pathologically low in 2 of 5 children studied. Disease-causing variants in HLH-associated genes were not found. All children were alive at latest follow-up (2–9 yrs after onset); neurological symptoms had normalized in 4 of 5 affected children.Conclusion: Moderately dosed etoposide may be beneficial in severe and/or refractory MAS-HLH.
- Open Access
- 11 August 2020
- Published by American Society of Hematology in Blood Advances
- Vol. 4 (15) , 3754-3766
Stem cell transplantation for children with hemophagocytic lymphohistiocytosis: results from the HLH-2004 study
We report the largest prospective study thus far on hematopoietic stem cell transplantation (HSCT) in hemophagocytic lymphohistiocytosis (HLH), a life-threatening hyperinflammatory syndrome comprising familial/genetic HLH (FHL) and secondary HLH. Although all patients with HLH typically need intensive anti-inflammatory therapy, patients with FHL also need HSCT to be cured. In the international HLH-2004 study, 187 children aged <18 years fulfilling the study inclusion criteria (5 of 8 diagnostic criteria, affected sibling, or molecular diagnosis in FHL-causative genes) underwent 209 transplants (2004-2012), defined as indicated in patients with familial/genetic, relapsing, or severe/persistent disease. Five-year overall survival (OS) post-HSCT was 66% (95% confidence interval [CI], 59-72); event-free survival (EFS) was 60% (95% CI, 52-67). Five-year OS was 81% (95% CI, 65-90) for children with a complete response and 59% (95% CI, 48-69) for those with a partial response (hazard ratio [HR], 2.12; 95% CI, 1.06-4.27; P = .035). For children with verified FHL (family history/genetically verified, n = 134), 5-year OS was 71% (95% CI, 62-78) and EFS was 62% (95% CI, 54-70); 5-year OS for children without verified FHL (n = 53) was significantly lower (52%; 95% CI, 38-65) (P = .040; HR, 1.69; 95% CI, 1.03-2.77); they were also significantly older. Notably, 20 (38%) of 53 patients without verified FHL had natural killer cell activity reported as normal at diagnosis, after 2 months, or at HSCT, suggestive of secondary HLH; and in addition 14 (26%) of these 53 children had no evidence of biallelic mutations despite having 3 or 4 FHL genes analyzed (natural killer cell activity not analyzed after 2 months or at HSCT). We conclude that post-HSCT survival in FHL remains suboptimal, and that the FHL diagnosis should be carefully investigated before HSCT. Pretransplant complete remission is beneficial but not mandatory to achieve post-HSCT survival. This trial was registered at www.clinicaltrials.gov as #NCT00426101.
- 11 August 2020
- Published by American Society of Hematology in Blood Advances
- Vol. 4 (15) , 3754-3766
Open AccessStem cell transplantation for children with hemophagocytic lymphohistiocytosis: results from the HLH-2004 study
We report the largest prospective study thus far on hematopoietic stem cell transplantation (HSCT) in hemophagocytic lymphohistiocytosis (HLH), a life-threatening hyperinflammatory syndrome comprising familial/genetic HLH (FHL) and secondary HLH. Although all patients with HLH typically need intensive anti-inflammatory therapy, patients with FHL also need HSCT to be cured. In the international HLH-2004 study, 187 children aged <18 years fulfilling the study inclusion criteria (5 of 8 diagnostic criteria, affected sibling, or molecular diagnosis in FHL-causative genes) underwent 209 transplants (2004-2012), defined as indicated in patients with familial/genetic, relapsing, or severe/persistent disease. Five-year overall survival (OS) post-HSCT was 66% (95% confidence interval [CI], 59-72); event-free survival (EFS) was 60% (95% CI, 52-67). Five-year OS was 81% (95% CI, 65-90) for children with a complete response and 59% (95% CI, 48-69) for those with a partial response (hazard ratio [HR], 2.12; 95% CI, 1.06-4.27; P = .035). For children with verified FHL (family history/genetically verified, n = 134), 5-year OS was 71% (95% CI, 62-78) and EFS was 62% (95% CI, 54-70); 5-year OS for children without verified FHL (n = 53) was significantly lower (52%; 95% CI, 38-65) (P = .040; HR, 1.69; 95% CI, 1.03-2.77); they were also significantly older. Notably, 20 (38%) of 53 patients without verified FHL had natural killer cell activity reported as normal at diagnosis, after 2 months, or at HSCT, suggestive of secondary HLH; and in addition 14 (26%) of these 53 children had no evidence of biallelic mutations despite having 3 or 4 FHL genes analyzed (natural killer cell activity not analyzed after 2 months or at HSCT). We conclude that post-HSCT survival in FHL remains suboptimal, and that the FHL diagnosis should be carefully investigated before HSCT. Pretransplant complete remission is beneficial but not mandatory to achieve post-HSCT survival. This trial was registered at www.clinicaltrials.gov as #NCT00426101.